 Top-line efficacy results from the B-SIMPLE program were announced in January 2020 with additional efficacy and safety analyses through Week 12 announced in February 2020. The B-SIMPLE program consisted of two multi-center, randomized, double-blind, vehicle-controlled pivotal trials B-SIMPLE1 and B-SIMPLE2 in 707 patients aged 6 months and older, with a 2:1 active:vehicle randomization. 